Brokerages forecast that Kura Oncology, Inc. (NASDAQ:KURA) will post earnings per share of ($0.41) for the current quarter, according to Zacks. Zero analysts have issued estimates for Kura Oncology’s earnings, with estimates ranging from ($0.49) to ($0.32). Kura Oncology reported earnings per share of ($0.37) during the same quarter last year, which suggests a negative year-over-year growth rate of 10.8%. The company is scheduled to issue its next earnings results on Monday, November 6th.

According to Zacks, analysts expect that Kura Oncology will report full-year earnings of ($1.64) per share for the current financial year, with EPS estimates ranging from ($1.82) to ($1.45). For the next year, analysts expect that the business will report earnings of ($2.20) per share, with EPS estimates ranging from ($2.70) to ($1.69). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that follow Kura Oncology.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Monday, August 7th. The company reported ($0.40) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.03.

Several analysts recently weighed in on the company. Zacks Investment Research raised Kura Oncology from a “hold” rating to a “buy” rating and set a $10.00 price objective on the stock in a research note on Thursday, May 18th. Cann reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Kura Oncology in a research note on Monday, May 15th. Cowen and Company assumed coverage on Kura Oncology in a research note on Thursday. They issued a “buy” rating on the stock. Oppenheimer Holdings, Inc. set a $16.00 price objective on Kura Oncology and gave the company a “buy” rating in a research note on Wednesday, June 14th. Finally, Citigroup Inc. set a $13.00 price objective on Kura Oncology and gave the company a “buy” rating in a research note on Tuesday, August 8th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. Kura Oncology currently has a consensus rating of “Buy” and a consensus price target of $14.15.

WARNING: “Zacks: Brokerages Expect Kura Oncology, Inc. (KURA) Will Announce Earnings of -$0.41 Per Share” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/09/07/zacks-brokerages-expect-kura-oncology-inc-kura-will-announce-earnings-of-0-41-per-share.html.

A number of large investors have recently added to or reduced their stakes in KURA. State of Wisconsin Investment Board acquired a new stake in Kura Oncology in the second quarter valued at about $102,000. Oppenheimer & Co. Inc. boosted its stake in Kura Oncology by 14.7% in the first quarter. Oppenheimer & Co. Inc. now owns 12,500 shares of the company’s stock valued at $110,000 after buying an additional 1,600 shares in the last quarter. Segantii Capital Management Ltd acquired a new stake in Kura Oncology in the first quarter valued at about $120,000. Rhumbline Advisers acquired a new stake in Kura Oncology in the second quarter valued at about $131,000. Finally, Nationwide Fund Advisors acquired a new stake in Kura Oncology in the first quarter valued at about $136,000. 39.07% of the stock is currently owned by institutional investors and hedge funds.

Shares of Kura Oncology (NASDAQ:KURA) traded down 1.44% during midday trading on Thursday, hitting $6.85. 1,003,652 shares of the stock traded hands. The company’s market capitalization is $136.92 million. Kura Oncology has a 1-year low of $4.00 and a 1-year high of $12.10. The stock has a 50 day moving average of $7.99 and a 200 day moving average of $8.70.

Kura Oncology Company Profile

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Get a free copy of the Zacks research report on Kura Oncology (KURA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.